Aizon Appoints Scott B. Waldman to Board of Directors
27 Feb 2024
Executive ChangeAcquisition
SAN FRANCISCO--(BUSINESS WIRE)--Aizon, an Artificial Intelligence (AI) SaaS provider that transforms pharmaceutical manufacturing operations, today announced the appointment of Scott B. Waldman to the Company’s Board of Directors (the “Board”), effective immediately. Mr. Waldman will serve as an Independent Director.
“I am pleased to welcome Mr. Waldman to Aizon’s Board of Directors, where he will play an integral role in supporting the execution of our strategy during this next pivotal phase of growth,” said Pep Gubau, Aizon CEO and co-founder. “Mr. Waldman brings a proven track record and valuable, hands-on experience advising companies through key moments of transformation and business development, and I am confident that his expertise and industry insights will strengthen our leadership and best position Aizon for the future. On behalf of the entire Board, we are looking forward to working alongside Scott as we continue to scale to support even more global customers.”
Mr. Waldman has led and advised life sciences companies for more than 25 years. He is founder and managing member of Waldman Growth Strategies, a strategy, M&A and legal consulting firm that supports private equity firms and life sciences companies through transactions and corporate milestones, with a focus on pharma and biotech contract development and manufacturing (CDMOs) and life science research and manufacturing. Prior to Waldman Growth Strategies, Mr. Waldman served as senior vice president, head of corporate development at Curia Global, a global CDMO where he led the company’s expansion into biologics through acquisitions, as well as leading corporate strategy and commercial functions. Prior to that, he spent 10 years at Lonza as U.S. general counsel and then as chief strategy officer, where he led Lonza’s M&A strategy, including the transformational $5.5 billion acquisition of Capsugel, and was integral to developing the company’s growth strategy and implementing initiatives that drove profitability. Before Lonza, Mr. Waldman was general counsel for Enzon Pharmaceuticals. He began his career in law in New York, first at Sidley Austin and then at Weil, Gotshal & Manges.
“Aizon’s innovative solutions address the tremendous opportunity to digitize pharmaceutical manufacturers’ operations and unlock the full potential of their data by harnessing technology,” said Mr. Waldman. “While manufacturers have made great strides to streamline their processes, Aizon’s technology leverages AI to further enhance efficiency and quality, and I am confident that Aizon has the ability to further revolutionize the industry with the upcoming launch of its next-generation eBR solution. I am thrilled to join such an innovative and dynamic company, and look forward to working closely with the Board and leadership team to take Aizon to the next level.”
About Aizon
Aizon stands at the forefront of pharmaceutical manufacturing innovation with its advanced, GMP-compliant, predictive analytics platform, distinguished by its unique combination of industrialized AI and contextualized Historian. This powerful synergy and the platform’s flexibility enable Aizon to provide unparalleled insights and enhanced decision-making capabilities in Pharma Manufacturing. For more information, please visit aizon.ai.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.